Publications by authors named "Puloma Pandey"
Article Synopsis
- Low-dose emicizumab has the potential to be a cost-effective treatment for hemophilia A, particularly beneficial in developing countries.
- A study compared the safety and efficacy of low-dose emicizumab (3 mg/kg monthly) against low-dose factor VIII prophylaxis (10-20 IU/kg twice a week) in two groups of patients.
- Results showed that low-dose emicizumab resulted in significantly better outcomes in various measures, with similar treatment costs compared to low-dose FVIII, making it a promising option for improving access to hemophilia treatment.
Purpose: Although cancer stem cells (CSCs) have been reported across solid tumors, there is a dearth of data regarding CSC and its impact on outcomes of cervical cancer.
Methods And Materials: From October 2013 to December 2015, patients with squamous cancer of the cervix (stage IB2-IVA) were included. Pretreatment and posttreatment biopsy was obtained and immunohistochemistry was performed for SOX-2, OCT-4, Nanog, CD44, and Podoplanin.